Mood-stabilizing medication (older drugs) plus basic psychosocial treatment for bipolar
Cost-effectiveness — what published models estimate per unit of health impact
$/DALY
$872–1501
WHO-CHOICE modeled
GiveWell
—
no GiveWell model
CE sources
2
Tier A · 37 studies
Source agreement
comparable
within 2.5×
Cost-effectiveness
Estimates are sourced in their native units and shown for comparison, not as literal costs. Sources use different frameworks — see each card for what it represents and how it was derived.
Modeled benchmarks ($/DALY)Tier A · standardized benchmark
WHO-CHOICE estimates are modeled at population-level population coverage, compared against the null set (no intervention) under generalized cost-effectiveness analysis. View WHO-CHOICE methodology →
$/DALY sources within 2.5x - treat as comparable, not ranked.
Modeled regional estimates — not realized delivery costs.
Published study estimates ($/DALY)Tier B · context only
Tufts GHCEA · 37 studies, varied methods — explore the spread, not a single number.
Health-system
$4,829
median · n=37
Filter the cohort
$4,829median of 37 studies · IQR $3,048–$7,233
Data completeness: not assessed (no country selected) · Evidence confidence: not assessed (no country selected)
Looking for supply/market data for Mood-stabilizing medication (older drugs) plus basic psychosocial treatment for bipolar? Select a country above, then open its intelligence page.